Current Flu vaccine News and Events

Current Flu vaccine News and Events, Flu vaccine News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
SARS-CoV-2 mutations do not appear to increase transmissibility
None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers, published in Nature Communications. (2020-11-25)

Fiji's vaccine program reduces childhood death and illness: study
Fiji's national vaccine program against pneumonia, a serious lung condition, and rotavirus, a common disease which causes severe diarrhoea and vomiting, has reduced illness and death, new research shows. (2020-11-25)

New therapy for flu may help in fight against COVID-19
A new therapy for influenza virus infections that may also prove effective against many other pathogenic virus infections, including HIV and COVID-19, has been developed by Purdue University scientists. The Purdue team's approach uses a targeted therapy approach against the virus infections. (2020-11-24)

Most adults over 50 say they'll get vaccinated against COVID-19, but many want to wait
A new poll of older adults - one of the highest-priority groups for COVID-19 vaccination - suggests an uphill climb lies ahead to reach the goal of widespread protection. In all, 58% of adults aged 50 to 80 say they are somewhat or very likely to get vaccinated to prevent COVID-19, but many say they want to wait until others are vaccinated first. (2020-11-24)

COVID19 A research of Politecnico di Milano discovering the secrets of viral sequences
Use of an algorithm for computing viral mutations homogeneously across sources, using cloud computing. (2020-11-23)

Therapeutic PD-1 cancer vaccine shown to be safe and effective in animal study
A study led by researchers at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) described a potential therapeutic anticancer vaccine that frees suppressed cancer-killing immune cells, enabling them to attack and destroy a tumor. (2020-11-23)

Proving viability of injection-free microneedle for single-administration of vaccines
A single-use, self-administered microneedle technology developed by UConn faculty to provide immunization against infectious diseases has recently been validated by preclinical research trials. Recently published in Nature Biomedical Engineering, the development and preclinical testing of the microneedle patches was reported by UConn researchers in the lab of Thanh Nguyen, assistant professor in the Departments of Mechanical Engineering and Biomedical Engineering. (2020-11-23)

Study: COVID-19 infection combined with blood clots worsen patient outcomes
While respiratory issues continue to be the most common symptom of a COVID-19 infection, new research indicates the disease could also be associated with an increased tendency of the blood to clot, leading to a higher risk of death from COVID-19. (2020-11-23)

MMR vaccine could protect against COVID-19
The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against COVID-19. In a new study published in mBio, an open-access journal of the American Society for Microbiology, researchers provide further proof of this by showing that mumps IgG titers, or levels of IgG antibody, are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with the MMR II vaccine produced by Merck (2020-11-20)

Study: TB vaccine linked to lower risk of contracting COVID-19
A widely used tuberculosis vaccine is associated with reduced likelihood of contracting COVID-19 (coronavirus), according to a new study by Cedars-Sinai. The findings raise the possibility that a vaccine already approved by the U.S. Food and Drug Administration may help prevent coronavirus infections or reduce severity of the disease. (2020-11-20)

COVID-19 News from Annals of Internal Medicine
Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine. (2020-11-20)

The Lancet: Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response
The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 years. The promising early stage results are published in The Lancet. (2020-11-19)

Experts issue recommendations for equitable distribution of COVID-19 vaccine
A group of vaccine experts led by Children's Hospital of Philadelphia (CHOP) has published recommendations to ensure equitable distribution of a COVID-19 vaccine when it becomes available. The framework, published today in Heath Affairs, focuses on five principles the authors believe would strengthen the current immunization delivery system to ensure equitable access to everyone for whom vaccination is recommended. (2020-11-19)

COVID-19 vaccine effectiveness to be affected heavily by infrastructure, public attitudes
The success of a COVID-19 vaccine will depend not only on its efficacy, but will hinge at least as much on how fast and widely it can be delivered, the severity of the pandemic, and the public's willingness to be immunized, according to a study published in Health Affairs. (2020-11-19)

Engineered immune cells elicit broad response to HIV in mice, offering hope for vaccine
Unlike so many other deadly viruses, HIV still lacks a vaccine. The virus has proven especially tricky to prevent with conventional antibodies, in part because it evolves so rapidly in the body. A solution would require coaxing the body into producing a special type of antibody that can act broadly to defeat multiple strains of the virus at once. Scientists at Scripps Research moved closer to attaining that goal with an approach that would rely on genetically engineered immune cells from the patient's body. (2020-11-19)

How the polio vaccine virus occasionally becomes dangerous
The polio vaccines, developed by Jonas Salk and Albert Sabin in the mid-1950s, heralded the elimination of polio from the U.S., saving countless children from sudden paralysis and death. In the developing world, however, outbreaks of poliovirus still occur sporadically, an ironic consequence of the polio vaccine itself. A new genetic study of the vaccine poliovirus reveals how this happens in real time. (2020-11-18)

High-dose equal to standard flu vaccine for risk of death or heart, lung hospitalization
A high-dose, trivalent influenza vaccine was no more effective than the standard-dose quadrivalent vaccine at reducing the risk of death or hospitalization for heart or lung-related causes among patients with heart disease. While overall there were few serious side effects in both vaccine groups, those who received the high-dose vaccine had more injection-related side effects such as pain, swelling and muscle aches. (2020-11-17)

'Meet people where they are:' local health departments key to hepatitis B vaccination
A study led by Stacy Tressler--who earned her doctorate in epidemiology from the West Virginia University School of Public Health--suggests that local health departments are vital to getting the hepatitis B vaccine to the people who need it most. (2020-11-17)

Are e-cigarette users at greater risk of poor immune response to flu, COVID?
In a controlled study of smokers, nonsmokers, and e-cigarette users, University of North Carolina School of Medicine researchers found that e-cigarette users exhibited significantly altered immune responses to a model of influenza virus infection, suggesting increased susceptibility to disease, including possibly COVID-19. (2020-11-17)

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M. Knipe and colleagues in this Perspective. (2020-11-17)

The Lancet Infectious Diseases: Chinese vaccine candidate based on inactivated SARS-CoV-2 virus appears safe and induces an immune response in healthy volunteers, preliminary study finds
Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published today in The Lancet Infectious Diseases journal, finding the formulation appears safe and induces an antibody response in healthy volunteers aged 18 to 59 years. (2020-11-17)

Researchers discover how to boost vaccine designed to prevent melanoma recurrence
A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic cells, according to phase 2 clinical trial results published in Nature Cancer in November. (2020-11-16)

Shutting Down COVID-19 virus' destructive proteins with aerosolized molecules
Researchers at Georgetown University Medical Center have successfully used molecules comprised of small strands of RNA to shut down the production of destructive proteins generated by the COVID-19 virus. Additionally, the researchers are working to aerosolize the RNA molecules so that they could be incorporated in an inhalable drug that would mitigate viral chaos. (2020-11-13)

Study: Respiratory failure in COVID-19 usually not driven by cytokine storm
A study by researchers at Washington University School of Medicine in St. Louis and St. Jude Children's Research Hospital in Memphis showed that, contrary to expectation, most people with severe COVID-19 do not suffer from unbridled inflammation. The findings suggest that anti-inflammatory therapies may not be helpful for most COVID-19 patients. (2020-11-13)

Cytokine storms play a limited role in moderate-to-severe COVID-19
St. Jude and Washington University researchers have discovered new characteristics that differentiate the response of COVID-19 from flu. (2020-11-13)

Examining impact of a point mutation in SARS-Cov-2 spike on virus transmission and pathogenicity
The current dominant variant of SARS-CoV-2, containing a D614G substitution in the spike protein, appears to have evolved to enhance transmissibility, according to a new study in human cells and animal models. (2020-11-12)

MTU, UMass researchers preserve viral vaccines without refrigeration
Half of vaccines are wasted annually because they aren't kept cold. Michigan Tech and UMass Amherst chemical engineers have discovered a way to stabilize viruses in vaccines with proteins instead of temperature. (2020-11-11)

Personalized cancer vaccine clinical trial to expand following promising early results
A University of Arizona Health Sciences clinical trial to study safety and effectiveness of a personalized cancer vaccine combined with immunotherapy drug Pembrolizumab will expand after promising preliminary data was presented at the Society for the Immunotherapy of Cancer's annual meeting. Researcher Julie E. Bauman, MD, MPH, reported data on the first 10 patients with head and neck cancer, seven of whom were treated at Banner - University Medicine, clinical partner for the UArizona Cancer Center. (2020-11-10)

A viable vaccine for tough tumors
While immunotherapies work well for some cancers, others are immune-resistant and condemn patients to the severe side effects of long-term chemo treatment. A new cancer vaccine successfully treated immune-resistant breast cancer in mice, 100% of which survived a second injection of cancer cells, indicating long-term immunity with no side effects. (2020-11-10)

Flu vaccine rate less than 25% in young adults with heart disease, despite increased risk
In 2018, only about 25% of adults between the ages of 18 and 34 with any cardiovascular disease received a flu shot, and in those with a history of a heart attack, only about 20% were vaccinated. Study authors hope their results will increase awareness among cardiologists, primary care physicians and the public about the protective benefits of flu vaccination. (2020-11-09)

Recommendations for fair and regulated access to a COVID-19 vaccine
The first COVID-19 vaccines could be authorized as early as the start of 2021. However, in all likelihood, there will not be sufficient vaccine doses in the beginning for all the people willing to undergo vaccination. This is why prioritization will be necessary. In the position paper published today, medical-epidemiological aspects of infection prevention are presented alongside ethical, legal and practical considerations. On this basis, the authors develop a framework for action for the initial prioritization of vaccination measures against COVID-19. (2020-11-09)

Could SARS-CoV-2 evolve resistance to COVID-19 vaccines?
Similar to bacteria evolving resistance to antibiotics, viruses can evolve resistance to vaccines, and the evolution of SARS-CoV-2 could undermine the effectiveness of vaccines that are currently under development, according to a paper published November 9 in the open-access journal PLOS Biology by David Kennedy and Andrew Read from Pennsylvania State University, USA. The authors also offer recommendations to vaccine developers for minimizing the likelihood of this outcome. (2020-11-09)

Vaccine shows promise against herpes virus
A genetically edited form of a herpes simplex virus has outperformed a leading vaccine candidate in a new study published in Nature Vaccines. When challenged with a virulent strain of the sexually transmitted HSV-2, vaccinated guinea pigs displayed fewer genital lesions, less viral replication and less of the viral shedding that most readily spreads infection. (2020-11-06)

Pay people to get COVID-19 jab to ensure widespread coverage, says leading ethicist
Governments should consider incentivising people to get a COVID-19 jab, when the vaccine becomes available, to achieve the required level of herd immunity--which could be up to 80%+ of the population--and stamp out the infection, argues a leading ethicist in an opinion piece accepted for publication in the Journal of Medical Ethics. (2020-11-05)

Study examines trends in symptoms experienced at the end of life
A new analysis published in the Journal of the American Geriatrics Society indicates that fewer older adults may be experiencing certain symptoms that can restrict their activity at the end of life. (2020-11-04)

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes. (2020-11-04)

Researchers identify key marker to help speed development of CMV vaccines
A Duke Health-led research team has identified a key marker that will help speed effective vaccine designs for cytomegalovirus (CMV), the most common congenital infection worldwide and a leading cause of infant brain damage. (2020-11-04)

Fighting Zika? Call in the T cells
In a new Science Advances study, Shresta and her colleagues at LJI report that the immune system's T cells have the power to prevent Zika infection in mice. This finding suggests that effective Zika vaccines need to activate T cells to work alongside antibodies. (2020-11-04)

Key populations for early COVID-19 immunization in Canada
Canada's National Advisory Committee on Immunization (NACI) recommends vaccinating key populations, such as people at risk of severe illness or death, those at risk of transmitting the virus and essential workers, during the initial rollout of a COVID-19 vaccine in Canada. The preliminary guidance, developed for the Public Health Agency of Canada (PHAC), is published in CMAJ (Canadian Medical Association Journal). (2020-11-03)

Ultrapotent COVID-19 vaccine candidate designed via computer
An ultrapotent nanoparticle candidate vaccine against COVID-19 has been developed with structure-based vaccine design techniques invented at UW Medicine. It is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 Spike protein's receptor-binding domain in a highly immunogenic array. The molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response. (2020-11-02)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.